Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry

2019

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL

Italian nationwide survey of pharmacologic treatments in diverticular disease: Results from the REMAD registry

01 Pubblicazione su rivista

Cremon C, Carabotti M, Cuomo R, Pace F, Andreozzi P, Barbaro Mr, Annibale B, Barbara G, on behalf of the REMAD Group, Andrealli A, Andriulli A, Ardizzone S, Astegiano M, Bachetti F, Bartolozzi S, Bargiggia S, Bassotti G, Bianco Ma, Binda Ga, Biscaglia G, Bosani M, Bottiglieri Me, Cargiolli M, Ciacci C, Colecchia A, Dell’Era A, De Matthaeis M, Dinelli M, Festa V, Festi D, Galliani E, Garribba A, Germana’ B, Grassini M, Guido E, Iafrate F, Iovino P, Iuliano D, Laghi A, Latella G, Lorusso M, Manes G, Marchi S, Mauro B, Maurano A, Nascimbeni R, Neri M, Occhipinti P, Parravicini M, Pennazio M, Peralta S, Portincasa P, Radaelli F, Rossi M, Salerno R, Savarino V, Segato S, Severi C, Scaccianoce G, Usai P, Valle V, Virgilio C, Viscido A

DOI: 10.1177/2050640619845990

ISSN: 2050-6406

Background: Although diverticular disease is a common condition, its effective treatment is challenging in clinical practice.
Objective: The objective of this article is to assess pharmacological management in different clinical settings of diverticular
disease and factors associated with treatment using the Italian registry Registro Malattia Diverticolare (REMAD).
Methods: At study enrolment, patients were categorised into subgroups: diverticulosis, symptomatic uncomplicated diverticular
disease and previous diverticulitis. We registered demographic, clinical and lifestyle factors, quality of life and the use
of treatments for diverticular disease in the last year. Logistic regression analysis assessed the association between clinical
factors and treatment consumption.
Results: A total of 500 of the 1206 individuals included had had at least one treatment for diverticular disease in the last
year: 23.6% (166/702) of patients with diverticulosis, 55.9% (165/295) of patients with symptomatic diverticular disease, and
80.9% (169/209) of patients with previous diverticulitis (p<0.001). In multivariate analysis, the following factors were
significantly associated with treatment use: female gender, family history of colonic diverticula, organic digestive comorbidity
and impaired physical quality of life components.
Conclusion: Individuals with diverticular disease take medications based on the different clinical settings of disease. We
identified different features associated with treatment use in the distinct clinical entities of diverticular disease.
ClinicalTrial.gov Identifier: NCT03325829.

Diverticulosis Management pharmacological treatments previous diverticulitis Registry symptomatic uncomplicated